Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour

European Radiology

Volumn 26, Issue 1, 2016, Pages 206-215

  Wagner, Mathilde ^a   Ronot, Maxime ^a,b   Doblas, Sabrina ^a   Giraudeau, Céline ^a   Van Beers, Bernard ^a,b   Belghiti, Jacques ^b   Paradis, Valérie ^b   Vilgrain, Valérie ^a,b  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Colorectal cancer; Diffusion weighted imaging; Lesion periphery; Liver metastases; Residual tumours

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GADOLINIUM CHELATE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; APPARENT DISSOCIATION CONSTANT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL LIVER METASTASIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; HUMAN TISSUE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE SCANNER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; COLORECTAL NEOPLASMS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES;

EID: 84948720161     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-015-3800-6     Document Type: Article

References (36)

1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254–259
2. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016
3. Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215
4. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657, discussion 657–648
5. Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN (2013) Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) 15:91–103
6. Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1061, discussion 1061–1054
7. Poultsides GA, Bao F, Servais EL et al (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 19:2797–2804
8. Rubbia-Brandt L, Giostra E, Brezault C et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299–304
9. Gruenberger T, Arnold D, Rubbia-Brandt L (2012) Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol 21:309–315
10. Blazer DG 3rd, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344–5351
11. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
12. Egger ME, Cannon RM, Metzger TL et al (2013) Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 216:845–856, discussion 856–847
13. Shindoh J, Loyer EM, Kopetz S et al (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:4566–4572
14. Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338–2344
15. Bruegel M, Gaa J, Waldt S et al (2008) Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and five t2-weighted turbo spin-echo sequences. AJR Am J Roentgenol 191:1421–1429
16. Eiber M, Fingerle AA, Brugel M, Gaa J, Rummeny EJ, Holzapfel K (2012) Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. Eur J Radiol 81:683–691
17. Parikh T, Drew SJ, Lee VS et al (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246:812–822
18. Soyer P, Boudiaf M, Place V et al (2011) Preoperative detection of hepatic metastases: comparison of diffusion-weighted, T2-weighted fast spin echo and gadolinium-enhanced MR imaging using surgical and histopathologic findings as standard of reference. Eur J Radiol 80:245–252
19. Zech CJ, Herrmann KA, Dietrich O, Horger W, Reiser MF, Schoenberg SO (2008) Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Investig Radiol 43:261–266
20. Wu LM, Hu J, Gu HY, Hua J, Xu JR (2013) Can diffusion-weighted magnetic resonance imaging (DW-MRI) alone be used as a reliable sequence for the preoperative detection and characterisation of hepatic metastases? A meta-analysis. Eur J Cancer 49:572–584
21. Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125
22. Youn BJ, Chung JW, Son KR et al (2008) Diffusion-weighted MR: therapeutic evaluation after chemoembolization of VX-2 carcinoma implanted in rabbit liver. Acad Radiol 15:593–600
23. Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104–4109
24. Geschwind JF, Artemov D, Abraham S et al (2000) Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 11:1245–1255
25. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR (2008) Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol 191:285–289
26. Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837
27. Koh DM, Scurr E, Collins D et al (2007) Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 188:1001–1008
28. Cui Y, Zhang XP, Sun YS, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248:894–900
29. Ng JK, Urbanski SJ, Mangat N et al (2008) Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study. Cancer 112:362–371
30. Mentha G, Terraz S, Morel P et al (2009) Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg 96:95–103
31. Brouquet A, Zimmitti G, Kopetz S et al (2013) Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 119:2778–2788
32. Maru DM, Kopetz S, Boonsirikamchai P et al (2010) Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287–1294
33. Goasguen N, de Chaisemartin C, Brouquet A et al (2010) Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. Int J Cancer 127:1028–1037
34. van Kessel CS, Samim M, Koopman M et al (2013) Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. Eur J Cancer 49:2486–2493
35. Chiaradia M, Baranes L, Van Nhieu JT et al (2014) Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis? J Magn Reson Imaging 39:317–325
36. Wagner M, Doblas S, Daire JL et al (2012) Diffusion-weighted MR imaging for the regional characterization of liver tumors. Radiology 264:464–472